CoChat

Time course of histological progression in primary biliary cirrhosis

Open access

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

Histological staging is used for stratification and assessment of treatment efficacy in therapeutic trials for primary biliary cirrhosis (PBC). Knowledge of the rate of progression of the histological changes would be helpful in the design (duration) and conduct of clinical trials. The histological stages were recorded for liver biopsies performed annually on 222 patients during a randomized, placebo- controlled clinical trial in which therapy with D-penicillamine (DPCA) was shown to be ineffective. These data were analyzed using a Markov model to describe the time course of histological progression in PBC. At study entry, 15 patients were stage I, 56 were stage II, 96 were stage III, and 55 were stage IV. Histological progression was observed after 1 year in 41%, 43%, and 35% of the patients, and after 2 years in 62%, 62%, and 50% of the patients who were stage I, stage II, and stage III at entry, respectively. After 4 years biopsies showed cirrhosis in 31% and 50% of the patients in stage I and stage II at entry, respectively. A minority (20%) of the precirrhotic patients showed histological stability; sustained histological regression was rarely observed (2%). Our data suggest that a majority of patients with PBC will progress histologically within 2 years. The distribution of histological stages over time may be helpful in determining the number of patients and length of time necessary to appreciate a treatment effect on histological progression in clinical trials for PBC.

Overview

Integrity signals

Registry

Crossref · 10.1002/hep.510230108

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 31 references

Cited by

See all 185

Metadata

Authors
Locke, G. R., Therneau, T. M., Ludwig, J., Dickson, E. R., & Lindor, K. D.
Affiliations
Mayo Clinic (US)
Venue
Hepatology
Published
1996-01
Volume
23
Issue
1
Pages
52-56
ISSN
0270-9139 (ISSN-L)
OpenAlex
W2112332162
Cited by
184
References
30
Citations by year
2026: 4 · 2025: 5 · 2024: 8 · 2023: 2 · 2022: 6 · 2021: 7 · 2020: 9 · 2019: 11 · 2018: 13 · 2017: 9 · 2016: 5 · 2015: 6 · 2014: 4 · 2013: 4 · 2012: 5
FWCI
5.21
Type
journal article
Language
en
Open access
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 7183 d)
Locations
  • Hepatology (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (DK 34-238-07A1)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Keywords
primary biliary cirrhosis, histological progression, histological staging, liver biopsy, D-penicillamine, Markov model, disease progression rate, histological regression, clinical trial design, treatment efficacy assessment
MeSH terms
Biopsy, Double-Blind Method, Female, Humans, Liver, Liver Cirrhosis, Biliary, Male, Markov Chains, Middle Aged, Penicillamine, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Time course of histological progression in primary biliary cirrhosis. https://app.cochat.ai/papers/10.1002/hep.510230108
The paper
Locke, G. R., Therneau, T. M., Ludwig, J., Dickson, E. R., & Lindor, K. D. (1996). Time course of histological progression in primary biliary cirrhosis. Hepatology. https://doi.org/10.1002/hep.510230108

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.